10-Q: OmniAb Reports Q2 2026 Results, Revenue Surges Amidst Net Loss

OmniAb, Inc. announced its second quarter 2026 financial results, showcasing a substantial increase in total revenue driven by license and milestone payments, while continuing to report net losses and a decrease in cash reserves.

Summary

• OmniAb, Inc. reported total revenue of $13.4 million for the three months ended June 30, 2026, a significant increase of 244% compared to $3.9 million in the same period of 2025.
• For the six months ended June 30, 2026, total revenue was $27.8 million, up 246% from $8.1 million in the prior year period.
• The company incurred a net loss of $5.9 million for the three months ended June 30, 2026, compared to a net loss of $15.9 million in the same period of 2025.
• For the six months ended June 30, 2026, the net loss was $13.6 million, compared to $34.1 million in the prior year period.
• Cash, cash equivalents, and restricted cash decreased to $24.9 million as of June 30, 2026, from $26.1 million as of December 31, 2025.
• The company had 110 active partners and 425 active programs as of June 30, 2026.
• 29 OmniAb-derived antibodies are in clinical development by partners, with two under regulatory review and three approved products.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to continued net losses, a decrease in cash and cash equivalents, and significant accumulated deficit, despite revenue growth.

Positives

• Total revenue for the three months ended June 30, 2026, increased by 244% to $13.4 million from $3.9 million in the prior year period.
• Total revenue for the six months ended June 30, 2026, increased by 246% to $27.8 million from $8.1 million in the prior year period.
• License and milestone revenue saw a significant increase of 666% to $9.5 million for the three months ended June 30, 2026.
• Service revenue increased by 28% to $2.5 million for the three months ended June 30, 2026.
• xPloration revenue increased by 91% to $1.2 million for the three months ended June 30, 2026.
• Royalty revenue increased by 140% to $0.3 million for the three months ended June 30, 2026.
• The number of active partners increased to 110 as of June 30, 2026, from 107 as of December 31, 2025.
• The number of active programs increased to 425 as of June 30, 2026, from 407 as of December 31, 2025.

Negatives

• The company reported a net loss of $5.9 million for the three months ended June 30, 2026, and $13.6 million for the six months ended June 30, 2026.
• Total costs and operating expenses were $20.1 million for the three months ended June 30, 2026, remaining relatively flat compared to $20.1 million in the prior year period.
• Cash, cash equivalents, and restricted cash decreased to $24.9 million as of June 30, 2026, from $26.1 million as of December 31, 2025.
• The company has an accumulated deficit of $179.7 million as of June 30, 2026.
• Research and development expenses were $9.6 million for the three months ended June 30, 2026, a decrease of 12% from the prior year period, but still a significant cost.
• General and administrative expenses were $6.7 million for the three months ended June 30, 2026, a decrease of 13% from the prior year period, but still a substantial expense.
• Amortization of intangibles increased by 41% to $9.1 million for the six months ended June 30, 2026, due to the write-off of certain legacy intangible assets.
• The company's warrants are currently out of the money, with an exercise price of $11.50, indicating a current stock price below this threshold.

Risks

• The company expects to continue to incur losses as it invests in research and development, market its technologies, and support its operations as a public company.
• The company's ability to continue operations is dependent on its ability to generate cash flows from operations and potentially obtain additional capital in the future.
• There is significant uncertainty in the timing and likelihood of reaching marketing authorization in drug discovery and development, and royalty payments may not become a material portion of revenue.
• The company does not control the progression, clinical development, regulatory strategy, or eventual commercialization of programs discovered using its platform, making it dependent on its partners' efforts.
• The company's license agreements are typically terminable by partners without penalty with specified notice, although milestone payments and royalties survive termination.
• The company's future capital requirements depend on various factors including revenue growth, operational costs, R&D progress, and market developments.
• The company's stock price is below the exercise price of its warrants, meaning warrant holders are unlikely to exercise them for cash, limiting potential capital infusion from this source.
• The company's business metrics are subject to risks and uncertainties related to its dependence on partners providing timely and accurate information.

Future Outlook

The company believes its existing cash, cash equivalents, and short-term investments are sufficient to support operations through at least the next 12 months. However, it anticipates continued losses due to investments in R&D and operational expansion. Future capital requirements will depend on revenue growth, operational costs, R&D progress, and market developments. The company may need to raise additional capital through equity or debt financing.

Management Comments

• "We believe the OmniAb animals comprise the most diverse host systems available in the industry."
• "Our license agreements with pharmaceutical and biotechnology partners generally include: (i) upfront or, in some instances, annual payments for technology access; (ii) payments for performance of research services; (iii) downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones; and (iv) royalties on net sales of our partners products, if any."
• "We believe the long-term value of our business will be driven by royalties given that such payments are based on global sales of potential future partner programs, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments."
• "Our business metrics are subject to risk and uncertainties related to our dependence on our partners providing timely and accurate information, which impacts our ability to objectively and accurately characterize the current level of activity for each program."

Industry Context

StockSavvy.ai notes that OmniAb operates in the competitive biotechnology sector, focusing on antibody discovery technology. The significant revenue growth, particularly in license and milestone revenue, reflects increased partner activity and success in achieving developmental milestones. However, the continued net losses and decrease in cash reserves highlight the capital-intensive nature of drug discovery and development, a common challenge for companies in this industry.

Comparison to Industry Standards

• The revenue growth rate of 244% for the six-month period is exceptionally high, significantly outperforming many early-stage biotechnology companies that are heavily reliant on R&D spending.
• The company's net loss, while reduced, is still substantial, which is typical for companies in the drug discovery phase that are investing heavily in R&D and clinical trials.
• The number of active partners (110) and active programs (425) indicates a strong market position and broad adoption of OmniAb's technology platform within the industry.
• The presence of 29 OmniAb-derived antibodies in clinical development, two under regulatory review, and three approved products suggests a robust pipeline and successful translation of its technology into potential therapeutics, aligning with industry benchmarks for promising biotech firms.

Legal Proceedings

• The company may be involved in various legal proceedings arising in its ordinary course of business. Management believes the resolution of any pending claims is not expected to have a material adverse impact, but acknowledges the inherent uncertainty of litigation outcomes.

Stakeholder Impact

• Shareholders: Continued net losses and a decrease in cash reserves may impact shareholder value. However, significant revenue growth and a reduced net loss could be viewed positively. The out-of-the-money warrants also limit immediate capital infusion potential.
• Employees: Share-based compensation continues to be a significant expense, indicating ongoing investment in employee incentives. Reductions in personnel costs due to reorganizations in 2025 may have impacted employee morale.
• Partners: The company's success is directly tied to its partners' success in developing and commercializing therapies. The increase in active partners and programs suggests strong relationships and continued collaboration.
• Creditors: The company's substantial accumulated deficit and reliance on future capital raises suggest a higher risk profile for creditors, though current liabilities appear manageable relative to assets.

Next Steps

• Continue to invest in research and development activities to improve the technology platform.
• Market and sell technologies to existing and new partners.
• Add operational, financial, and management information systems and personnel to support operations.
• Continue to monitor and manage cash flows and liquidity.
• Potentially raise additional capital through equity or debt financing if needed.
• Continue to track active partners and programs to assess business performance.
• Monitor the progression of partner programs in clinical development and regulatory review.

Key Dates

Recommendation

While OmniAb demonstrates impressive revenue growth and a reduction in net loss, the company continues to operate at a significant loss with a substantial accumulated deficit. The decrease in cash reserves and the out-of-the-money warrants present ongoing liquidity concerns. The positive revenue trajectory and pipeline development warrant a 'hold' recommendation, pending clearer signs of profitability or a successful capital raise that strengthens the balance sheet.

Keywords

biotechnology, drug discovery, antibody technology, licensing, milestone payments, royalty revenue, research and development, clinical development